Download PDF

1. Company Snapshot

1.a. Company Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers.The company operates in two segments, CooperVision and CooperSurgical.The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.


The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide.It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing.The Cooper Companies, Inc.


was founded in 1958 and is headquartered in San Ramon, California.

Show Full description

1.b. Last Insights on COO

Breaking News: The Cooper Companies, Inc. reported better-than-expected fourth-quarter earnings and provided upbeat financial guidance. The company's Q4 earnings and sales beat estimates, driven by rising demand for MyDay and strong momentum for MiSight. Cooper Companies is launching a portfolio review to "unlock value". The company's Q4 2025 earnings call transcript and key metrics are available for review. Some analysts have noted the positive results, but no specific buy, hold, or sell recommendations have been made based on this information.

1.c. Company Highlights

2. Cooper Companies' Q4 2025 Earnings: A Strong Finish to the Year

The Cooper Companies reported a record Q4 2025 revenue of $1.065 billion, representing a 4.6% year-over-year increase, or 3.4% on an organic basis. Non-GAAP earnings per share (EPS) came in at $1.15, beating analyst estimates of $1.11, reflecting an 11% growth. The company's gross margin decreased in Q4, but it expects operating margin leverage due to controlled SG&A growth. CooperVision's revenue was $710 million, up 4.9% or 3.2% organically, driven by the strong performance of its MyDay premium daily silicone hydrogel lens portfolio.

Publication Date: Dec -07

📋 Highlights
  • Revenue Growth: Q4 revenue hit $1.065B (+4.6% YoY), while organic growth stood at 3.4%.
  • Non-GAAP Earnings: Surged 11% to $1.15, reflecting strong operational performance.
  • MyDay Lens Momentum: CooperVision’s MyDay portfolio neared $400M annualized, despite Clarity lens sales declining 2%.
  • Free Cash Flow & Repurchases: $2.2B+ FCF target for 2026–2028 and a $2B share buyback plan announced.
  • Market Growth Outlook: Contact lens market forecasted for 4–5% growth in 2026, driven by MyDay expansion and Asia-Pacific recovery.

Segment Performance

CooperVision's MyDay lens sales were particularly strong, approaching $400 million on an annualized basis. In contrast, Clarity lens sales were down a couple of percent, but the company is repositioning Clarity in certain markets to make it more entry-level. CooperSurgical revenue was $356 million, up 4% or 3.9% organically, driven by solid execution in fertility and office and surgical sales.

Guidance and Outlook

The company guided for fiscal 2026 consolidated revenues of $4.3 billion to $4.34 billion, reflecting 4.5% to 5.5% organic growth. Non-GAAP EPS is expected to be between $4.45 and $4.6 in fiscal 2026. CooperCompanies expects to generate over $2.2 billion in free cash flow from fiscal 2026 through 2028 and has raised its fiscal 2026 to 2028 free cash flow target.

Valuation and Growth Prospects

With a P/E Ratio of 43.01 and an EV/EBITDA of 19.73, the market seems to be pricing in significant growth prospects for Cooper Companies. Analysts estimate next year's revenue growth at 5.7%. The company's plans to allocate about two-thirds of its free cash flow to share repurchases in 2026, which will be EPS accretive, and its exploration of strategic alternatives, including a potential separation of its businesses, are expected to drive long-term shareholder value.

Operational Highlights

The company is undergoing a strategic review and is considering various options to create long-term value. CooperVision's free cash flow outlook improved, driven by consistent performance and working capital management. The company is also repositioning its Clarity lens product in certain markets and is optimistic about the growth prospects for its PARAGARD product.

3. NewsRoom

Card image cap

Cooper Companies Launches Portfolio Review To 'Unlock Value'

Dec -05

Source: benzinga.com

Card image cap

COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises

Dec -05

Source: zacks.com

Card image cap

Stock Market Today: Dow Slips, Nasdaq Futures Gain As Investors Await Release Of Fed's Preferred Inflation Data— Netflix, Cooper Cos In Focus

Dec -05

Source: feeds.benzinga.com

Card image cap

Victoria's Secret, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Friday

Dec -05

Source: feeds.benzinga.com

Card image cap

The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call Transcript

Dec -05

Source: seekingalpha.com

Card image cap

The Cooper Companies (COO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Dec -05

Source: zacks.com

Card image cap

The Cooper Companies (COO) Q4 Earnings and Revenues Surpass Estimates

Dec -04

Source: zacks.com

Card image cap

Cooper Companies initiates strategic review; shares jump

Dec -04

Source: reuters.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.00%)

6. Segments

CooperVision

Expected Growth: 6.0%

CooperVision's 6.0% growth is driven by increasing demand for silicone hydrogel contact lenses, expansion in emerging markets, and strategic investments in digital marketing and e-commerce platforms. Additionally, the company's focus on innovative products, such as daily disposable lenses, and its strong relationships with eye care professionals contribute to its growth momentum.

CooperSurgical

Expected Growth: 6.0%

CooperSurgical's 6.0% growth driven by increasing demand for women's healthcare and fertility treatments, expansion in emerging markets, and strategic acquisitions. Additionally, investments in product innovation and digitalization are enhancing customer experience, contributing to revenue growth.

7. Detailed Products

Clariti 1-Day

Daily disposable contact lenses designed for comfort and clarity

Clariti 1-Month

Monthly disposable contact lenses for clear and comfortable vision

Biofinity

Monthly disposable contact lenses for astigmatism and presbyopia

Avaira

Two-weekly disposable contact lenses for comfort and clarity

Paragon CRT

Orthokeratology (OK) lenses for overnight wear to correct vision

Syringeal IOL

Intraocular lenses for cataract surgery

Clariti 1-Day Toric

Daily disposable contact lenses for astigmatism

8. The Cooper Companies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for The Cooper Companies, Inc. is medium due to the presence of alternative products and services in the medical device industry.

Bargaining Power Of Customers

The bargaining power of customers for The Cooper Companies, Inc. is low due to the company's strong brand reputation and diversified product portfolio.

Bargaining Power Of Suppliers

The bargaining power of suppliers for The Cooper Companies, Inc. is medium due to the presence of multiple suppliers in the market, but the company's large scale of operations gives it some bargaining power.

Threat Of New Entrants

The threat of new entrants for The Cooper Companies, Inc. is low due to the high barriers to entry in the medical device industry, including regulatory hurdles and high research and development costs.

Intensity Of Rivalry

The intensity of rivalry for The Cooper Companies, Inc. is high due to the presence of several established competitors in the medical device industry, leading to intense competition for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 25.39%
Debt Cost 5.75%
Equity Weight 74.61%
Equity Cost 8.81%
WACC 8.03%
Leverage 34.02%

11. Quality Control: The Cooper Companies, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Merit Medical Systems

A-Score: 4.4/10

Value: 2.6

Growth: 7.3

Quality: 6.5

Yield: 0.0

Momentum: 2.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
DENTSPLY SIRONA

A-Score: 4.0/10

Value: 7.7

Growth: 1.4

Quality: 3.1

Yield: 6.0

Momentum: 0.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Teleflex

A-Score: 3.6/10

Value: 4.7

Growth: 3.4

Quality: 5.4

Yield: 1.0

Momentum: 0.5

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Repligen

A-Score: 3.0/10

Value: 0.2

Growth: 5.0

Quality: 3.9

Yield: 0.0

Momentum: 5.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Cooper

A-Score: 2.9/10

Value: 2.9

Growth: 1.2

Quality: 5.9

Yield: 0.0

Momentum: 1.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Azenta

A-Score: 2.8/10

Value: 5.1

Growth: 2.6

Quality: 4.2

Yield: 0.0

Momentum: 1.5

Volatility: 3.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

82.46$

Current Price

82.46$

Potential

-0.00%

Expected Cash-Flows